You are here: Industry Insights > Spikevax

News List

Second COVID-19 vaccine ‘Spikevax’ is approved by the FDA EuropeanPharmaceuticalReview
February 10, 2022
The FDA has approved a second vaccine, marketed as Spikevax, shown to be 93 percent effective in preventing COVID-19.
FDA takes key action by approving second COVID-19 vaccine WorldPharmaNews
February 07, 2022
The U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine.
Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine prnasia
December 20, 2021
Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®.
Moderna Spikevax Receives Marketing Authorization in Korea contractpharma
December 16, 2021
The Moderna COVID-19 vaccine manufactured at Samsung Biologics’ local production facilities can be distributed in Korea and exported to other countries.
Health Canada Authorizes the Use of The Moderna Spikevax COVID-19 Vaccine as a Booster Shot AmericanPharmaceuticalReview
November 17, 2021
Health Canada has authorized the use of the Moderna Spikevax COVID-19 vaccine as a booster shot. A COVID-19 booster shot is an extra dose of the vaccine given after completion...
UK authorises Moderna's COVID-19 vaccine Spikevax for adolescents firstwordpharma
August 18, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday extended the conditional authorisation for Moderna's mRNA COVID-19 vaccine Spikevax, allowing it to be given to 12- to 17-year-olds in Great Britain.
EMA committee recommends Moderna’s Covid-19 vaccine for adolescents pharmaceutical-technology
July 27, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the marketing authorisation of the Moderna Covid-19 vaccine, Spikevax, for adolescents aged 12 to 17 years.